Top Markets
Coin of the day
ReNeuron Group plc ReNeuron Group plc

ReNeuron Group plc

RENE
Classifica tra le azioni #41656
Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc... Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.
Prezzo delle azioni
$0.00042815
Ultima sincronizzazione: 2024-02-27
Capitalizzazione di mercato
$13.55K
Variazione (1 giorno)
0.03%
Variazione (1 anno)
0.00%
Paese
GB
Scambia ReNeuron Group plc (RENE)

Categoria

Cronologia dei frazionamenti azionari per ReNeuron Group plc (RENE)
L’azione ReNeuron Group plc (simbolo: RENE) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 13, 2026.
Una quota di RENE acquistata prima di Aug 13, 2026 equivale oggi a 0 quote di RENE.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
NL
0 -
CH
0 -
BE
0 -
KR